Immorna Receives Grant from Bill & Melinda Gates Foundation to Support Its mRNA RSV Vaccine Clinical Development
Summary
As a biotech company developing mRNA-based vaccines and therapeutic drugs, Immorna closely follows the global needs for prevention of infectious diseases and strive to help provide more treatment options to patients in needs and contribute the creation of a disease-free, better future. We are on track to enroll the first subject for our clinical trial by the end of Aug 2024.JCXH-108 is a monovalent RSV vaccine being developed by Immorna using its proprietary mRNA and RTU-LNP technologies. JCXH-108 features a mild storage and transportation condition with shelf life of approximately 18 months at 2-8 \xb0C, which greatly improve the mRNA vaccines accessibility. Immunization of cotton rats with low dose of JCXh-1108 achieved complete protection against RSV virus challenge.Immorna is a rapidly expanding biotechnology company, focusing on the development of RNA-based therapeutics and vaccines. Since its founding in 2019, Immorna has built a robust CMC platform for RNA synthesis, purification, and analytical testing that is well suited for clinical and commercial development.